Description
Release form
Enteric-coated tablets.
Packing
30 pcs.
Pharmacological action
CardiASK – NSAIDs, antiplatelet agent.
The main mechanism of action of CardiASK is irreversible inactivation of the cyclooxygenase enzyme (COX-1), as a result of which thromboxane A2 synthesis is blocked and platelet aggregation is suppressed. CardiASK also has anti-inflammatory, antipyretic and analgesic effects.
Indications
Prevention of acute myocardial infarction in the presence of risk factors (including diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and myocardial infarction
Unstable angina pectoris sardlkp patients with transient cerebrovascular diseases)
Prevention of transient cerebrovascular disorders
Prevention of thromboembolism after surgery and invasive vascular interventions (including coronary artery bypass grafting, en darterectomy of carotid arteries, arteriovenous bypass surgery, carotid artery angioplasty)
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including with prolonged immobilization as a result of extensive surgery).
Contraindications
Hypersensitivity to acetylsalicylic acid and other NSAIDs
erosive and ulcerative lesions of the gastrointestinal tract
gastrointestinal bleeding
bronchial asthma induced by the use of salivylate and trifida bronchial arrhythmias: recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid)
hemorrhagic diathesis
combined use with methotrexate at a dose of 15 mg per week or more
hepatic insufficiency
renal failure
I and mild third term pregnancy .
Caution: prescribed for gout, hyperuricemia, as well as for patients with a history of gastrointestinal ulcer or gastrointestinal bleeding, bronchial asthma, chronic respiratory diseases, hay fever, nasal mucosa polyposis, allergic reactions to drugs, when combined with methotrexate in doses of less than 15 mg per week, with a deficiency of vitamin K and glucose-6-phosphate dehydrogenase.
Special instructions
CardiAsk should be used after prescribing a doctor.
ASA can provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors are a history of asthma, hay fever, nasal polyposis, chronic diseases of the respiratory system, as well as allergic reactions to other drugs (eg, skin reactions, itching, urticaria).
ASA can cause bleeding of varying severity during and after surgery.
The combination of ASA with anticoagulants, thrombolytics and antiplatelet drugs is associated with an increased risk of bleeding.
ASA in low doses can trigger the development of gout in susceptible individuals (with decreased uric acid excretion).
The combination of ASA with methotrexate is accompanied by an increased incidence of side effects from the blood.
High doses of ASA have a hypoglycemic effect, which must be kept in mind when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.
The combined use of corticosteroids and salicylates should be remembered that during treatment, the level of salicylates in the blood is reduced, and after the cancellation of corticosteroids, an overdose of salicylates is possible.
The combination of ASA with ibuprofen is not recommended, since the latter worsens the beneficial effect of ASA on life expectancy.
An excess dose of ASA is associated with a risk of gastrointestinal bleeding.
Overdose is especially dangerous in elderly patients.
Combined with ASA and alcohol, there is an increased risk of damage to the gastrointestinal mucosa and prolonged bleeding time.
Composition
1 tablet contains 50 mg acetylsalicylic acid.
Dosage and administration of
CardiASK should be taken orally, before meals, with plenty of fluids.
CardiASK is intended for long-term use. The duration of therapy is determined by the attending physician.
Prevention of suspected acute myocardial infarction: 100-200 mg / day or 300 mg every other day (the first tablet must be chewed for faster absorption).
Prevention of first-time acute myocardial infarction in the presence of risk factors: 100 mg per day or 300 mg every other day.
Prevention of myocardial infarction, unstable angina, prevention of stroke and transient cerebrovascular accident, prevention of
Thromboembolic complications after surgery or invasive studies: 100-300 mg per day
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches: 100-200 mg per day or 300 mg every other day.
Side effects
Allergic reactions: urticaria, Quincke’s edema.
From the digestive tract: nausea, heartburn, vomiting, pain in the abdomen, ulcers of the mucous membrane of the stomach and duodenum, including perforated, gastrointestinal bleeding, increased activity of liver enzymes.
From the respiratory system: bronchospasm.
On the part of the immune system: anaphylactic reactions.
From the hemopoietic system: anemia (rarely), increased bleeding.
From the central nervous system: dizziness, tinnitus.
Patient interaction
When combined KardiASK enhances methotrexate effects by reducing its renal clearance and displacement of the links to plasma proteins.
With the simultaneous use of CardiASA, it enhances the action of heparin and indirect anticoagulants due to impaired platelet function and displacement of indirect anticoagulants from bonds with blood plasma proteins.
CardiASA, when combined, enhances the effect of thrombolytic and antiplatelet drugs (including ticlopidine).
CardiASK increases the concentration of digoxin in blood plasma by reducing renal excretion and enhances its effects.
CardiASK enhances the action of hypoglycemic drugs (insulin and sulfonylurea derivatives) due to the hypoglycemic effect of acetylsalicylic acid (in high doses) and displacement of sulfonylurea derivatives from the association with blood plasma proteins.
CardiASK enhances the action of valproic acid by displacing the latter from its association with plasma proteins.
When used together, CardiAAS weakens the effect of uricosuric drugs (benzbromarone) due to competitive tubular elimination of uric acid.
With the simultaneous use of GCS, they enhance the excretion of salicylates and weaken their effect.
With simultaneous use with ethanol, an additive effect is noted.
Overdose
Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment: dose reduction.
Severe overdose symptoms:
fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.
Treatment: immediate hospitalization in specialized departments for emergency therapy – gastric lavage, determination of acid-base condition, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When carrying out alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when the concentration of salicylates in the blood plasma is more than 500 mg / l (3.6 mmol / l) in adults and 300 mg / l (2 , 2 mmol / l) in children.
Storage Conditions
In a dry, dark place at a temperature not exceeding 25 ° C. Keep out of the reach and sight of children.
pharmacy terms and conditions without a prescription
Form of Treatment tablets
Appointment Only
Beremenn m II trimester doctor on purpose, Vzrosl m
Indications
Prevention of genital infections, Herpes, For tonsillitis, For sinusitis, For stomatitis, Chlamydia, Otitis, Vaginitis, For trichomoniasis, Sore throat, For sore throat, For skin infections, Postpartum infections, Othelagitis
Prevention of thrombosis, From cerebrovascular accidents, From angina, Prevention of acute myocardial infarction, Prevention of heart attacks and strokes, Prevention of thromboembolism
Possible product names
Carvedilol tablets 12.5 mg 30 pcs pldroffrd 18fprdrofd18pdrofrd 0.05 N30 TABLE P / O
CardiASK 50mg Tab. cover captivity. intestines. about. X30 (R)
CardiASK 50mg No. 30
CardiASK tablet p / o 50mg x 30
CardiASK tablet p / o enteric 50mg N30 (control unit N30)
Kanonfarma, Russia
